Inhibitor Therapeutics (INTI) Dividends payables (2018 - 2022)
Inhibitor Therapeutics' (INTI) quarterly Dividends payables came in at $250413.0 in Q3 2022, up 396.74% YoY from $50411.0 in Q3 2021, and up 25.21% on a QoQ basis from $200002.0 in Q2 2022.
Inhibitor Therapeutics (INTI) Dividends payables (2018 - 2022) Analysis & Trends
Inhibitor Therapeutics (INTI) has 5 years of Dividends payables data on file, last reported at $250413.0 in Q3 2022.
- Quarterly Dividends payables rose 396.74% year-over-year to $250413.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $250413.0 (up 396.74% YoY) and the FY2021 annual result came in at $100823.0, changed 0.0% from the prior year.
- Dividends payables climbed to $250413.0 in Q3 2022, from $200002.0 in the prior quarter.
- In the past five years, Dividends payables ranged from a high of $250413.0 in Q3 2022 to a low of $26630.0 in Q1 2018.
- A 5-year average of $101848.8 and a median of $99178.0 in 2019 frame the typical range for Dividends payables.
- Annual changes were most pronounced in 2021 — Dividends payables slumped 67.27% — and 2022, when it jumped 396.74%.
- Tracing INTI's Dividends payables over 5 years: stood at $99945.0 in 2018, then advanced by 0.88% to $100822.0 in 2019, then changed by 0.0% to $100822.0 in 2020, then grew by 0.0% to $100823.0 in 2021, then jumped by 148.37% to $250413.0 in 2022.
- The last three Dividends payables figures came in at $250413.0 (Q3 2022), $200002.0 (Q2 2022), and $150138.0 (Q1 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dividends payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 250,413.00 |
| Jun 30, 2022 | 200,002.00 |
| Mar 31, 2022 | 150,138.00 |
| Dec 31, 2021 | 100,823.00 |
| Sep 30, 2021 | 50,411.00 |
| Jun 30, 2021 | 99,178.00 |
| Mar 31, 2021 | 49,315.00 |
| Dec 31, 2020 | 100,822.00 |
| Sep 30, 2020 | 50,411.00 |
| Jun 30, 2020 | 200,548.00 |
| Mar 31, 2020 | 150,685.00 |
| Dec 31, 2019 | 100,822.00 |
| Sep 30, 2019 | 50,410.00 |
| Jun 30, 2019 | 99,178.00 |
| Mar 31, 2019 | 49,315.00 |
| Dec 31, 2018 | 99,945.00 |
| Sep 30, 2018 | 49,534.00 |
| Jun 30, 2018 | 56,548.00 |
| Mar 31, 2018 | 26,630.00 |